{"id":"https://genegraph.clinicalgenome.org/r/1e06156f-3a60-4e0c-bf47-ed68ad831af1v1.0","type":"EvidenceStrengthAssertion","dc:description":"Per Criteria outlined by the ClinGen Lumping and Splitting working group, we found no difference in molecular mechanism or inheritance pattern underlying the disease entities: (1) Sideroblastic anemia with B-cell immunodeficiency, periodic fevers, and developmental delay (SIFD), (MIM:616084) and (2) Retinitis pigmentosa and erythrocytic microcytosis, (MIM:616959).\nTherefore, evidence favor lumping the entities (MIM:616084 and MIM:616959) to a single disease spectrum.\n\nTRNT1 (CCA-adding tRNA nucleotidyl transferase enzyme) performs an essential post- transcriptional modification by adding on the cytosine- cytosine-adenine (CCA) trinucleotide sequence to the 3′ end of all newly produced tRNAs. This TRNT1- dependent tRNA modification is essential for both cytosolic and mitochondrial tRNAs (mt-tRNAs) to participate in protein biosynthesis. \n\nMutations in *TRNT1* were first reported to cause a syndrome characterized by congenital sideroblastic anemia, B-cell immunodeficiency, recurrent fevers and developmental delay (referred to as SIFD) in 2014 (PMID: 25193871). Retinitis pigmentosa and erythrocytic microcytosis were also reported in SIFD patients (PMID: 27370603).\n\n2 frameshift , 2 splicing , and 3 missense TRNT1 variants are used in this curation. Mechanism of pathogenicity seems to be loss of function resulting in impaired ability of TRNT1 to catalyze the formation of the CCA trinucleotide (PMID: 25193871)\n\nExperimental evidence also supports this gene-disease relationship. Phenotypes of the lumped diseases could be recapitulated in Zebrafish model system through the same molecular pathway. Morphological analysis of the MO-injected embryos (morphants) revealed cardiovascular defects and reduced eye size in addition to  reduced staining of hemoglobin-containing red blood cells and significantly reduced touch response. RNA sequencing confirmed that Morphants had a significantly lower CCA incorporation efficiency than controls (PMID: 26494905). Mt-tRNAs lacking CCA are also detected in patients’ fibroblasts compared to controls (PMID: 27370603).\n\nIn summary, *TRNT1* is definitively associated with the disease spectrum Sideroblastic anemia with B-cell immunodeficiency, periodic fevers, and developmental delay (SIFD) and Retinitis pigmentosa and erythrocytic microcytosis. This has been repeatedly demonstrated in both the research and clinical diagnostic settings and has been upheld over time. This classification was approved by the ClinGen Antibody Deficiencies GCEP on October 7, 2022.","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/1e06156f-3a60-4e0c-bf47-ed68ad831af1","GCISnapshot":"https://genegraph.clinicalgenome.org/r/6df64a62-650c-4659-b2e8-ee51263fcdbc","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/6df64a62-650c-4659-b2e8-ee51263fcdbc_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10080","date":"2022-10-30T12:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/6df64a62-650c-4659-b2e8-ee51263fcdbc_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10080","date":"2023-01-24T20:56:50.308Z","role":"Publisher"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6df64a62-650c-4659-b2e8-ee51263fcdbc_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f48d907a-a5fd-4eb5-a7fe-5c1736795e2d_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d883c009-68e8-4af7-84a6-899af2658141","type":"EvidenceLine","dc:description":"The variant affects a donor splice site in intron 5\nIn trans with the c.461 C>T substitution in the proband 11 PMID 25193871\nVarSEAK Class 5 Loss of function for authentic Splice Site. Exon Skipping\ngnomAD 0.0000893899\nExperimental studies have shown that this variant disrupts mRNA splicing\n results in a shorter transcript \n","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d883c009-68e8-4af7-84a6-899af2658141_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Experimental studies have shown that this variant disrupts mRNA splicing\n results in a shorter transcript ","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/d883c009-68e8-4af7-84a6-899af2658141_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25193871","allele":{"id":"https://genegraph.clinicalgenome.org/r/0f0ddf8c-93eb-460d-93d3-93ece530bc6b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_182916.3(TRNT1):c.608+1G>T","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2228721"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/4a20979e-996d-4c6b-ab1a-4d4f13df4e87","type":"EvidenceLine","dc:description":"The variant is transition in exon 4, resulting in a thr154-to-ile \nhighly conserved residues in the active site\n\nexpression of the mutant TRNT1  provided \nonly partial rescue \n","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4a20979e-996d-4c6b-ab1a-4d4f13df4e87_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Expression of the mutant TRNT1  provided \nonly partial rescue","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/4a20979e-996d-4c6b-ab1a-4d4f13df4e87_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25193871","allele":{"id":"https://genegraph.clinicalgenome.org/r/fc61e947-8841-4462-8009-317333bea84c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_182916.3(TRNT1):c.461C>T (p.Thr154Ile)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA249575"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/f48d907a-a5fd-4eb5-a7fe-5c1736795e2d","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25193871","rdfs:label":"Chakraborty_P11","allele":[{"id":"https://genegraph.clinicalgenome.org/r/fc61e947-8841-4462-8009-317333bea84c"},{"id":"https://genegraph.clinicalgenome.org/r/0f0ddf8c-93eb-460d-93d3-93ece530bc6b"}],"firstTestingMethod":"Genotyping","phenotypes":["obo:HP_0001924","obo:HP_0032323","obo:HP_0005363"],"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/d883c009-68e8-4af7-84a6-899af2658141_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/4a20979e-996d-4c6b-ab1a-4d4f13df4e87_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/7a385bdb-5a31-4ad9-b927-e3f733da2961_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/aa501da4-79f3-4447-b3f1-8e5ae494f844","type":"EvidenceLine","dc:description":"1bp duplication causing a frameshift predicted to result in a protein with 6 incorrect amino acids that is truncated by 9 amino acids. p.Ser418LysfsTer9.\n\nReported in several individuals affected with sideroblastic anemia with B-cell immunodeficiency, fevers and developmental delay (PMID: 29358286, 25193871)\n\nsegregated with autosomal recessive retinitis pigmentosa and microcytosis in a family (PMID: 26494905).\n\nWestern blot analysis of protein extracted from patient fibroblasts showed significantly decreased levels of TRNT1 protein compared to controls\n","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/aa501da4-79f3-4447-b3f1-8e5ae494f844_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Western blot analysis of protein extracted from patient fibroblasts showed significantly decreased levels of TRNT1 protein compared to controls","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/aa501da4-79f3-4447-b3f1-8e5ae494f844_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25193871","allele":{"id":"https://genegraph.clinicalgenome.org/r/a6570861-377c-4d67-80ec-a01fa9d52d15","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_182916.3(TRNT1):c.1252dup (p.Ser418LysfsTer9)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2228924"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/7a385bdb-5a31-4ad9-b927-e3f733da2961","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25193871","rdfs:label":"Chakraborty_P14","allele":{"id":"https://genegraph.clinicalgenome.org/r/a6570861-377c-4d67-80ec-a01fa9d52d15"},"firstTestingMethod":"Genotyping","phenotypes":["obo:HP_0001924","obo:HP_0005363","obo:HP_0032323"],"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/aa501da4-79f3-4447-b3f1-8e5ae494f844_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/fd95e234-7f0a-4070-87e3-1af1751b476a_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1d2a52e2-fd2a-4120-a708-9b2a9dc7d93a","type":"EvidenceLine","dc:description":"The variant was detected in 2 Pakistani siblings (1A and 1B) and another unrelated  proband (8)\nexon 5 of the TRNT1 gene, resulting in an arg190-to-ile (R190I) substitution at a highly conserved residue in the active site. Functional data (impaired ability to catalyze CCA formation and impaired stability of the resultant mutant protein)also support varint pathogenecity.\ngnomAD highest MAF in Latino/Admixed American  0.00003372. \n","calculatedScore":4,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1d2a52e2-fd2a-4120-a708-9b2a9dc7d93a_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"The missense mutation impaired the ability of TRNT1 to catalyze the formation of the CCA trinucleotide. Moeover, altered stability of the protein has been demonstrated. ","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/1d2a52e2-fd2a-4120-a708-9b2a9dc7d93a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25193871","allele":{"id":"https://genegraph.clinicalgenome.org/r/7acc1d7b-214d-4a9c-a69f-68b845f903ec","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_182916.3(TRNT1):c.569G>T (p.Arg190Ile)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA249568"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":6},{"id":"https://genegraph.clinicalgenome.org/r/fd95e234-7f0a-4070-87e3-1af1751b476a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25193871","rdfs:label":"Chakraborty_P1","allele":{"id":"https://genegraph.clinicalgenome.org/r/7acc1d7b-214d-4a9c-a69f-68b845f903ec"},"firstTestingMethod":"Linkage analysis","phenotypeFreeText":"B-cell lymphopenia  and developmental delay","phenotypes":["obo:HP_0032323","obo:HP_0001924"],"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/1d2a52e2-fd2a-4120-a708-9b2a9dc7d93a_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/90a8f8aa-62d8-48fa-8c5d-b8647344c852_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5138e1e3-985f-4d52-b589-b77ad4c4f43d","type":"EvidenceLine","dc:description":"a 4-bp insertion (c.1142_1143insATGT) in exon 8, resulting in a frameshift and premature termination (Trp381fs), and I223T \nDetected in trans with the c.668T>C substitution in the proband 13 (Chakraborty et al. (2014) \n","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5138e1e3-985f-4d52-b589-b77ad4c4f43d_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"yes","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/5138e1e3-985f-4d52-b589-b77ad4c4f43d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25193871","allele":{"id":"https://genegraph.clinicalgenome.org/r/539e5b6e-7d8a-4568-89d3-9acf81da09cd","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_182916.3(TRNT1):c.1142_1143insATGT (p.Trp381Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA249577"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/90a8f8aa-62d8-48fa-8c5d-b8647344c852","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25193871","rdfs:label":"Chakraborty_P13","allele":{"id":"https://genegraph.clinicalgenome.org/r/539e5b6e-7d8a-4568-89d3-9acf81da09cd"},"firstTestingMethod":"Linkage analysis","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/5138e1e3-985f-4d52-b589-b77ad4c4f43d_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/f242737a-f705-4ec1-b2f4-50af55a69180_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/95f5cb6e-6b4e-4412-9ffe-18d59346a857","type":"EvidenceLine","dc:description":"The p.I223T substitution lies at the neck of the crystal structure of the protein. \nReported in 8 patients with SIFD disease (2,3,4,9,13,14 compound heterozygous ) and proband 6 (homozygous)\nPMID: 25193871 and  proband with SIFD disease and retinitis pigmentosa\n(PMID: 27370603). \nInvitro studies show reduced stability and altered catalytic efficiency  PMID: 29454993\ngnomAD -  MAF: 3.18 × 10-5, Highest  MAF in European non-Finnish : 7.89 × 10-5\nAbout 80% of individuals who died carried the  mutation.\n\n","calculatedScore":4,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/95f5cb6e-6b4e-4412-9ffe-18d59346a857_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Invitro studies show reduced stability and altered catalytic efficiency  PMID: 29454993","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/95f5cb6e-6b4e-4412-9ffe-18d59346a857_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25193871","allele":{"id":"https://genegraph.clinicalgenome.org/r/52663b0a-039d-4c07-a178-e641f9f4559c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_182916.3(TRNT1):c.668T>C (p.Ile223Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA249570"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":6},{"id":"https://genegraph.clinicalgenome.org/r/f242737a-f705-4ec1-b2f4-50af55a69180","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25193871","rdfs:label":"Chakraborty_P6","allele":{"id":"https://genegraph.clinicalgenome.org/r/52663b0a-039d-4c07-a178-e641f9f4559c"},"firstTestingMethod":"Linkage analysis","phenotypes":["obo:HP_0032323","obo:HP_0005363","obo:HP_0001924"],"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/95f5cb6e-6b4e-4412-9ffe-18d59346a857_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/963f985e-c31f-45bf-9a1e-b7f389cb598f_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/58d711ed-6589-4ea6-9f73-aa0936d2049e","type":"EvidenceLine","dc:description":"Splicing at ivs 7\nDetected Intrans with c.668T>C substitution 3 individuals (patients 2, 3, and 9)  with SIFD disease\nVarSEAK class 5 splicing effect, exon skipping\ngnomAD AF 0.000131091\n Strongly predicted by the Human Splicing Finder to result in a new splice acceptor site \n inserts 6 nucleotides in the complementary DNA upstream of exon 8, encoding the insertion of sequential threonine and TAG stop codons (p.D352_S353insTX) and premature termination of the protein\n","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/58d711ed-6589-4ea6-9f73-aa0936d2049e_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"strongly predicted by the Human Splicing Finder to result in a new splice acceptor site \n that inserts 6 nucleotides in the complementary DNA upstream of exon 8, encoding the insertion of sequential threonine and TAG stop codons (p.D352_S353insTX) and premature termination of the protein\n","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/58d711ed-6589-4ea6-9f73-aa0936d2049e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25193871","allele":{"id":"https://genegraph.clinicalgenome.org/r/2b41dbcc-09ed-46a6-ad13-397fbe4027ad","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_182916.3(TRNT1):c.1057-7C>G","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA249572"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/963f985e-c31f-45bf-9a1e-b7f389cb598f","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25193871","rdfs:label":"Chakraborty_P2","allele":{"id":"https://genegraph.clinicalgenome.org/r/2b41dbcc-09ed-46a6-ad13-397fbe4027ad"},"firstTestingMethod":"Genotyping","phenotypeFreeText":"Developmental delay","phenotypes":["obo:HP_0001924","obo:HP_0005363","obo:HP_0032323"],"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/58d711ed-6589-4ea6-9f73-aa0936d2049e_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/6df64a62-650c-4659-b2e8-ee51263fcdbc_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6df64a62-650c-4659-b2e8-ee51263fcdbc_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e7a13e6f-9901-4586-9651-aa7b94f6cce7","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/29b3c781-2ab2-4219-ae61-671a1b295cc5","type":"Finding","dc:description":"Morphological analysis of the MO-injected embryos (morphants) \nrevealed cardiovascular defects and reduced eye size\n\nMorphants exhibited reduced staining of hemoglobin-containing red \nblood cells and significantly reduced touch response. TRNT1 deficient patients also exhibit  anaemia and retinitis pigmentosa. \n\nAlso, demonstrated  Morphants had a significantly lower CCA incorporation efficiency than controls.\nA sequential injection of trnt1MO \nfollowed by hTRNT1 RNA resulted in a significantly higher\nresponse compared with morphant siblings \n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26494905","rdfs:label":"Zebrafish recapitulated features of the human SIFD ","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/6df64a62-650c-4659-b2e8-ee51263fcdbc_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7a5d7bc6-6e53-45be-b777-1f7568d9451c","type":"EvidenceLine","dc:description":"TRNT1 performs an essential post- transcriptional modification by adding on the cytosine- cytosine-adenine (CCA) trinucleotide sequence to the 3′ end of all newly produced tRNAs. \nTRNT1- dependent tRNA modification is essential for both cytosolic and mitochondrial tRNAs (mt-tRNAs) to participate in protein biosynthesis. \nThe CCA trinucleotide sequence is required to accurately attach amino acids, to position the tRNA on the ribosome and to conclude protein translation. Impaired ability of the mutant protein to catalyze the formation of the CCA trinucleotide has been demonstrated in most of the patients  and in the Zebrafish model system.\n","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/486f8770-86be-4017-b8f6-c48a4f76ec34","type":"Finding","dc:description":"TRNT1 mutations were confirmed to result in impaired its of TRNT1 to catalyze the formation of the CCA trinucleotide. Most mutant proteins detected in TRNT1 deficient patients had no detectable activity","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27370603","rdfs:label":"Defect in maturation of the 3’ end of mt-tRNA ","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":3}],"evidenceStrength":"Definitive","sequence":5827,"specifiedBy":"GeneValidityCriteria9","strengthScore":15,"subject":{"id":"https://genegraph.clinicalgenome.org/r/rtlTRb5nWPQ","type":"GeneValidityProposition","disease":"obo:MONDO_0014487","gene":"hgnc:17341","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_6df64a62-650c-4659-b2e8-ee51263fcdbc-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}